- Home
- UAL vs WAT Comparison
UAL vs WAT Comparison
Compare UAL & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAL
- WAT
- Stock Information
- Founded
- UAL 1934
- WAT 1958
- Country
- UAL United States
- WAT United States
- Employees
- UAL N/A
- WAT N/A
- Industry
- UAL Air Freight/Delivery Services
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- UAL Consumer Discretionary
- WAT Industrials
- Exchange
- UAL Nasdaq
- WAT Nasdaq
- Market Cap
- UAL 26.5B
- WAT 17.8B
- IPO Year
- UAL N/A
- WAT 1995
- Fundamental
- Price
- UAL $102.61
- WAT $302.49
- Analyst Decision
- UAL Strong Buy
- WAT Hold
- Analyst Count
- UAL 15
- WAT 14
- Target Price
- UAL $109.14
- WAT $374.07
- AVG Volume (30 Days)
- UAL 4.7M
- WAT 582.9K
- Earning Date
- UAL 10-14-2025
- WAT 10-31-2025
- Dividend Yield
- UAL N/A
- WAT N/A
- EPS Growth
- UAL 13.06
- WAT 10.77
- EPS
- UAL 9.98
- WAT 11.09
- Revenue
- UAL $57,986,000,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- UAL $4.43
- WAT $7.19
- Revenue Next Year
- UAL $7.57
- WAT $6.40
- P/E Ratio
- UAL $10.48
- WAT $26.89
- Revenue Growth
- UAL 4.23
- WAT 5.89
- 52 Week Low
- UAL $50.31
- WAT $275.05
- 52 Week High
- UAL $116.00
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- UAL 51.39
- WAT 52.51
- Support Level
- UAL $105.06
- WAT $294.96
- Resistance Level
- UAL $110.66
- WAT $303.24
- Average True Range (ATR)
- UAL 3.30
- WAT 8.88
- MACD
- UAL -0.79
- WAT 0.66
- Stochastic Oscillator
- UAL 9.65
- WAT 66.28
About UAL United Airlines Holdings Inc.
United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large US peers.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.